About this trial
The goal of this clinical trial is to learn if the use of MRI-guided asymmetric ultrahipofractionated irradiation (2 fractions with dose increase in the tumor areas and dose sparing in urethra, rectum and neurovascular bundles) produces similar results in terms of local control and complications to standard 5-fraction SBRT.
Eligibility criteria
Qualifiers
No prior radiation therapy to the target areas
Expected patient survival >5 years
Patient able to undergo a MRI exam
Suboptimal candidates for high-dose therapy such as elderly, frail patients or patients with large volume glands (i.e, >60cm3) or extensive TURP in the prior 6-12 months should be considered cautionary indications.
Disqualifiers
Prior radiation therapy to the target areas
Expected patient survival below 5 years
Patient unable to undergo a MRI exam
Trial design
Treatments tested in this trial
- MR-Guided SBRT